RxDoctor Payments Data

Shirley Cirillo, MD

Neurology · Rochester, NYNPI 1316927007

Payments from drug & device makers

$5,653in general payments, 2019–2025

Across 74 payments — averaging $76.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$4K
  • Amgen$364
  • Biogen$300
  • Teva Pharmaceuticals USA, Inc.$223
  • Pfizer$181
  • Livanova USA, Inc.$110
  • plus $391 from 12 others

What the payments were for

  • Consulting fees$1503%
  • Speaking & faculty fees$3,51862%
  • Travel & lodging$4798%
  • Food & beverage$1,50727%

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,653 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$11,741
Medicare patients
45
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab12$103,146
CopaxoneGlatiramer Acetate15$81,940
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$68,664
Nurtec OdtRimegepant Sulfate42$62,434
Aimovig AutoinjectorErenumab-Aooe59$51,756
AptiomEslicarbazepine Acetate11$24,270
Lamictal XrLamotrigine22$20,569
VimpatLacosamide24$15,329
BotoxOnabotulinumtoxina12$14,353
Emgality PenGalcanezumab-Gnlm21$14,154
Lacosamide108$9,869
Ajovy SyringeFremanezumab-Vfrm11$7,413
Sumatriptan Succinate43$7,059
Carbamazepine ErCarbamazepine31$5,483
Rasagiline Mesylate38$4,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$223$81,94015 claims
PfizerNurtec Odt$181$62,43442 claims
Sunovion Pharmaceuticals Inc.Aptiom$71$24,27011 claims
UCB, Inc.Vimpat$56$15,32924 claims
AbbVieBotox$13$14,35312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →